Skip to content
OpenCapital
Get started

OraSure Technologies OSUR Risk Assessment Testing — Net revenues

Other product segments

HIV
$13.02M+0.9%
Sample Management Solutions
$9.06M-0.6%
HCV
$2.66M-38.5%
Other Product And Services Revenues
$1.62M+109%
Non-product and services revenues
$1.55M+65.8%
COVID-19
$18K-96.1%

Similar metrics at other companies

Veracyte logo
VCYTTesting revenue — Total Revenue
$135.09M+25.9%
GeneDx Holdings logo
WGSDiagnostic Test — Total Revenue
$101.3M+18.1%
Rhythm Pharmaceuticals, Inc. logo
RYTMProduct revenue, net — Total revenues
$60.11M+59.4%
Ardelyx logo
ARDXProduct sales, net — Total revenues
$93.37M+37.7%
Teradyne, Inc. logo
TERProduct Test — Revenue
$80.44M+8.4%
Esperion Therapeutics logo
ESPRProduct sales, net — Total Revenues
$43.4M+24.3%

Other financials

Income statement

See full
Revenue$27.9M-6.7%
Gross profit$11.8M-4.0%
Operating income-$23.3M-31.1%
Net income-$22.4M-39.5%
EPS (diluted)-$0.32-52.4%

Balance sheet

See full
Cash & equivalents$177.0M-28.5%
Total debt$12.7M-10.9%
Total equity$313.3M-20.9%
Total assets$379.2M-17.1%

Cash flow

See full
Operating cash flow-$13.9M+29.6%
CapEx$913.0K+117%
Free cash flow-$14.8M+26.5%

Valuation

See full
Market cap$303.62M+35.3%
Enterprise value$139.32M-1,654%
P/S2.7×+1.3×

Profitability

See full
Gross margin42.2%+0.4pp
Operating margin-68.6%-149pp
Net margin-66.4%-115pp
FCF margin-42.4%-43.3pp

Returns & leverage

See full
Return on equity-21.2%-50.4pp
Debt / equity0×0.0×
Current ratio5.5×-6.9×

Where this comes from

Reported directly by OraSure Technologies in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: OraSure Technologies’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about OraSure Technologies's risk assessment testing — net revenues.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is OraSure Technologies's risk assessment testing — net revenues?
OraSure Technologies (OSUR) reported risk assessment testing — net revenues of $0 in Q1 2026.
How has OraSure Technologies's risk assessment testing — net revenues changed year-over-year?
OraSure Technologies's risk assessment testing — net revenues decreased by 100.0% year-over-year, from $1.42M to $0.
What is the long-term trend for OraSure Technologies's risk assessment testing — net revenues?
Over 4 years (2021 to 2025), OraSure Technologies's risk assessment testing — net revenues has grown at a -33.7% compound annual growth rate (CAGR), from $9.68M to $1.87M.
What does risk assessment testing — net revenues mean?
This metric represents the total revenue generated from the sale of diagnostic products and services specifically designed for risk assessment and screening. It reflects the market demand for specialized testing solutions used to identify health risks or infectious disease exposure. Monitoring this revenue stream helps evaluate the commercial performance and growth trajectory of the company's dedicated risk assessment business unit.